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Diagnostic criteria were heterogeneous and included deﬁ nitions based on International 
Classiﬁ cation for Headache Disorders (ICHD) guidelines, Silberstein-Lipton criteria, 
and various investigator-deﬁ ned frequency-based classiﬁ cations. Thus, deﬁ nitions
varied from relatively strict criteria (q15 days/month of migraine) to more liberal cri-
teria (history of migraine and q15 days/month of headache). Prevalence of CM was 
0%-5.1%, with estimates typically in the range of 1.4%-2.2%. Seven studies used 
criteria of history of migraine and q15 days/month of headache (or equivalent), with 
prevalence of 0.9%-5.1%. Three studies used criteria of q15 days/month of migraine
(or equivalent), with prevalence of 0%-0.7%. Two studies stated that the condition 
was transformed migraine or chronic migraine (without speciﬁ c criteria), with preva-
lence of 1.6% and 4.1%. Prevalence varied by WHO region and gender. CONCLU-
SIONS: CM prevalence estimates are inﬂ uenced by speciﬁ c deﬁ nitions employed.
Using the strictest criteria, prevalence was well under 1%; with a less restrictive deﬁ ni-
tion, prevalence was higher, 1%-5%. With these variations, it is difﬁ cult to compare 
results across regions and explore temporal trends. Future studies on CM would 
beneﬁ t from an ICHD consensus diagnosis that is clinically appropriate and opera-
tional in large-scale epidemiological studies.
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OBJECTIVES: Prevalence data of Alzheimer’s disease and related dementia (ADRD) 
in managed care organizations (MCO) is old and very few data on the prevalence of 
the co-existing conditions. This study aims at investigating the rates and the trend of 
the prevalence of ADRD and the co-existing conditions in MCO over an eleven- year 
period. METHODS: Data are drawn from the Ingenix Impact National Managed Care 
Database (Impact Database). The study time period is 1997–2007. Annual prevalence
of ADRD and two common co-existing conditions (type II diabetes and congestive 
heart failure) are calculated among those aged q50 and those aged q65. Prevalence of 
the co-existing conditions among ADRD patients are compared to the prevalence
among the general population in the same age group. Data extraction and prevalence
calculations are performed in SAS 9.1. RESULTS: From 1997 to 2001, prevalence of 
ADRD increased dramatically among those aged 50 and aged 65. Prevalence of ADRD 
starts to level off during 2005–2007 in both age groups. For the two co-morbid condi-
tions that are investigated, 1) prevalence of diabetes is 2.3 times higher in ADRD 
patients than in the general population, prevalence of congestive heart failure is 5 
times higher; and 2) during 1997–2007, prevalence of both co-morbid conditions 
among ADRD patients are constantly increasing, whereas the prevalence in the general 
population are variant. CONCLUSIONS: In this study, prevalence estimates of ADRD 
are consistent with the literature. The ﬁ nding that the prevalence of ADRD starts to 
level off since 2005 may indicate that for persons under the care of MCO, the under-
diagnose of ADRD may drop to a certain level in recent years. The substantially higher
prevalence of co-morbid conditions among ADRD patients and its constantly increas-
ing trend may pose both challenge and opportunity to MCO managers in their strate-
gies for containing costs.
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OBJECTIVES: Worldwide, data on the long term prognosis of Parkinson’s disease 
(PD) are limited, particularly in South-east Asia. This study was carried out to inves-
tigate the time taken to transit between Hoehn & Yahr (H&Y) stages among patients 
with PD in Singapore. METHODS: Patients were recruited from a tertiary neurosci-
ence clinic in Singapore. Both patients’ clinical and demographic information were
obtained from hospital’s database. Time-to-transition was computed using Kaplan-
Meier analysis. Cox regression analysis was performed to examine the inﬂ uence of 
gender, race, duration of PD and age-at-diagnosis on time-to-transition. RESULTS: A
total of 695 patients (mean age: 65.3, male: 58%) consented to participate in the 
study. Using Kaplan-Meier analysis, the time-to-transition from H&Y stage 1 to 2, 
from 2 to 2.5, from 2.5 to 3 were 22.3, 52.9 and 30.3 months, respectively. Time-to-
transition from stage 3 to 4, and from stage 4 to 5 were 27.4 and 30.0 months, 
respectively. In Cox regression analysis, younger-onset (age at diagnosis  83.6 as refer-
ence group, p  0.006; age at diagnosis  56.1, f p  1.713, p  0.011) and shorter 
PD duration (duration  14.7 as reference group, p  0.002; duration  4.9, f p 
2.188, p  0.001; duration  7.5, f p  1.443, p  0.030) predicted longer time-to-
transition from stage 2 to 2.5. Shorter PD duration (duration  22.8, p  0.021) simi-
larly predicted longer duration from stage 4 to 5. CONCLUSIONS: To the best of 
our knowledge, this is the ﬁ rst study to report on disease progression using time-to-
transition between various H&Y stages. Our ﬁ ndings were similar from current litera-
ture in that younger-onset patients took longer to reach advanced stages. However, 
unlike published literature, disease progression was not slower among female com-
pared to male patients in our study. This could be a real difference or could be due
to different ways of measuring disease progression. The data are thus interesting and 
worth further exploration. These information are also important to clinicians to help
improve patient management.
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OBJECTIVES: To assess the proportion of patients with epilepsy switching back to 
branded lamotrigine after generic substitution, to investigate the possible clinical 
consequences of generic substitution in Germany, and to compare the results with 
published research data. German national guidelines recommend not to switch stable
epileptic patients to a generic version of the anti-epileptic drug (AED). METHODS:
Retrospective IMS Disease Analyzer with longitudinal data (January 2005 to July 
2008) was used. An open-cohort design was used to classify patients’ observation into
mutually-exclusive periods of branded versus generic use of lamotrigine. Periods of 
generic use were further stratiﬁ ed into single-generic, multiple-generic use, and switch-
back-cohort. Published results from Québec’s provincial health care-plan (RAMQ) 
from April 1998 to July 2006 were used as comparator. Patients with at least one 
diagnosis for epilepsy (ICD-10: G40.x) and at least one prescription of Lamotrigine 
(ATC-N03A0) were selected. RESULTS: A total of 1,171 patients (674 female
(57.5%), mean age 39.0, SD 17.4) were observed in the German data. Compared to 
the RAMQ database, we found a similar distribution of patients’ demographics, 
periods of brand use and generic switching. In the switch-group, 30.3 % of patients
switched back to branded lamotrigine. There was a statistically signiﬁ cant difference
between brand and generic periods for mean (paired t-test, p  0.0001) and median 
(sign-test, p  0.0001) daily dose. In contrast, the group switching from branded to
generic and back to branded lamotrigine showed no signiﬁ cant difference in the mean 
(p  0.4482) and median daily dose (p  0.7744). CONCLUSIONS: Lamotrigine 
patients in Germany switching from brand to generic lamotrigine experienced similar
clinical consequences of generic substitution, as reported previously, also for other 
AEDs. Given the same characteristics as here, results can be transferred to a different 
population. Therefore, we expect comparable clinical consequences and switch back 
patterns for topiramate generic substitution in Germany.
NEUROLOGICAL DISORDERS – Cost Studies
PND6
COMPARISON OF COSTS FOR INTERFERON BETA 1-A AND
NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
Kozma C1, Dickson M2, Meletiche DM3
1University of South Carolina, West Columbia, SC, USA, 2University of South Carolina, 
Columbia, SC, USA, 3EMD Serono, Inc, Rockland, MA, USA
OBJECTIVES: To compare cost of care for interferon beta (IFNB)-1a subcutaneous 
(SC) and natalizumab in patients with multiple sclerosis (MS). METHODS: In this 
post hoc analysis, eligible patients (18 and 65 years) had an MS diagnosis in a
national managed care database, q1 new medical or prescription claim for IFNB-1a 
SC or natalizumab during the July 1, 2006 to December 31, 2006 selection period,
and were continuously eligible for 12 months before and after the initial disease-
modifying drug (DMD) claim in the selection period. Managed care costs represented
both total and component costs. A propensity score was calculated as the probability 
of being in either treatment group from preperiod variables (eg, age, sex, region). 
Analysis of covariance was used to evaluate total and component costs by treatment 
cohort. RESULTS: A total of 421 patients (IFNB-1a SC  222, natalizumab  199) 
met study criteria. Most patients were women (IFNB-1a SC, 77.9%; natalizumab, 
74.4%), but were older in the natalizumab group (mean [SD] 45.5 [9.7] y vs 42.2 
[10.7] y). DMD use differed by region, and more natalizumab patients were enrolled 
in HMOs (43.2% vs 32.4%). The percentage of patients with no evidence of DMD
use in the preperiod was 26.6% for natalizumab and 63.5% for IFNB-1a SC. Least
square (LS) means differences between IFNB-1a SC and natalizumab for total and 
prescription costs were a function of the number of days of exposure. At the average 
exposure of 290 days, total LS mean cost for IFNB-1a SC and natalizumab were 
$26,433 and $35,980, respectively (P  0.0001). Prescription costs were signiﬁ cantly
higher for natalizumab compared with IFNB-1a SC ($26,775 vs $20,187; P  0.0001). 
Outpatient costs were signiﬁ cantly greater for natalizumab patients ($8640) than for
IFNB-1a SC patients ($4930; P  0.0001). CONCLUSIONS: Patients initiated on 
natalizumab had greater total, prescription, and outpatient costs than did patients 
initiated on IFNB-1a SC.
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OBJECTIVES: To assess the impact of headache frequency on health care utilization,
medication use, productivity loss, and total costs. METHODS: The American
Migraine Prevalence and Prevention (AMPP) Study is a 5-year, national, longitudinal
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survey of headache in the United States. This study utilized data collected in the 2005 
baseline survey of 14,544 adults who were identiﬁ ed as having migraine based on
criteria proposed by the International Classiﬁ cation of Headache Disorders, 2nd
edition. Participants completed self-administered, validated questionnaires on head-
ache features, frequency, impairment, resource and medication use, and productivity
loss. Direct and indirect headache-related costs were estimated using unit-cost assump-
tions derived from the PharMetrics Patient-Centric database, wholesale acquisition 
costs of medications, and wage data from the US Bureau of Labor Statistics. The 
population of migraineurs was divided into quartiles (1–2, 3–6, 7–16, and 17–365
headache days) based on self-reported headache frequency in the past year. Analyses 
controlled for age, gender, income, geographic region, population density, and insur-
ance status. RESULTS: Of the original 14,544 identiﬁ ed migraine cases, 12,829 com-
pleted the 2005 survey and were included in this analysis. Higher headache frequency 
quartile was associated with more nights in hospital and increased visits to primary
care, urgent care, pain clinic, emergency room, and neurologists or headache special-
ists. The most commonly cited medications used for headache relief in all four quartiles
were non-prescription analgesics and NSAIDs, and the most commonly cited prescrip-
tion medications in all quartiles were the triptans. Lost productive time (but not
absenteeism) generally increased progressively in the higher quartiles. Average per-
person annual total costs, including direct and indirect costs, ranged from $2528 
(lowest quartile) to $6014 (highest quartile). CONCLUSIONS: Decreasing headache
frequency is associated with positive economic beneﬁ ts of reduced resource use and
productivity loss. These beneﬁ ts should be considered by stakeholders interested in 
improving migraine outcomes in a cost-effective fashion.
PND8
THE IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON
HEALTH CARE COSTS: CONVERSION OF THE CANADIAN EXPERIENCE
INTO THE SETTINGS OF G4 EUROPEAN COUNTRIES
Paradis PE1, Latremouille-Viau D1, Lafeuille MH1, Lefebvre P1, Gaudig M2, Duh M3
1Groupe d’analyse, Ltee, Montreal, QC, Canada, 2Janssen-Cilag, Neuss, Germany, 3Analysis 
Group, Inc., Boston, MA, USA
OBJECTIVES: Examine the economic impact of generic substitution of the antiepi-
leptic drug (AED) topiramate in Canada; and convert observed Canadian costs into 
the settings of France, Germany, Italy, and the UK. METHODS: Health claims from
Québec’s provincial health plan (RAMQ) between January 2006 and September 2008 
were analyzed. Patients with epilepsy or non-febrile convulsions (ICD-9: 345, 780.3 
or 780.39) and q2 topiramate (Topamax) dispensings were selected. An open-cohort
design was used to classify patients’ observation into mutually-exclusive periods of 
branded versus generic use of topiramate. Total health care utilization and costs in 
Canada (C$2007/person-year) were compared between periods of branded versus 
generic use, after adjusting for demographics, treatment characteristics, and comor-
bidities. Annualized health care costs (€2007 and L2007/person-year) were converted
at the patient level using Canadian utilization rates, adjusted with service-use ratios 
and European unit costs. Non-parametric bootstrap procedure was used to determine
statistical signiﬁ cance for the cost measures. RESULTS: A total of 1164 patients (mean 
age: 39.8 years, 61.7% female) were observed for 2.6 years on average. Unadjusted 
results consistently associated generic use with signiﬁ cant increases in health care
resource utilization. Periods of generic topiramate use remained associated with sig-
niﬁ cant increases in pharmacy dispensings (other AEDs: 6%, non-AEDs: 31%, p 
.001), a 17% increase in hospitalizations (p  0.015), and 21% longer lengths of 
hospital stays (p  .001). Non-topiramate adjusted health care costs were C$1,060/
person-year higher during periods of generic use (p  0.005). Converted per-patient
health care costs excluding topiramate were estimated to be signiﬁ cantly higher for
generic relative to brand periods in all four countries (adjusted cost differences per 
person-year [95% CI]: France: €815 [€427–€1.215], Germany: €706 [€369–€1058], 
Italy: €795 [€430–€1177], UK: L485 [L283-L687]; p  0.001 for all comparisons).
CONCLUSIONS: Higher health care costs were projected for G4 European countries
from the Canadian experience following generic substitution of topiramate, offsetting 
potential savings from lower generic prices.
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OBJECTIVES: To evaluate the cost-effectiveness of using Apolipoprotein E (APOE)
testing and preventive treatment with Donepezil for Mild Cognitive Impairment (MCI)
patients and to consider various scenarios of positive gene distribution and treatment
strategies. METHODS: A decision tree was constructed to the costs and effects of the
intervention: an APOE predictive genetic test and preventive treatment with donepezil 
in the MCI population. Clinical data from a RCT conducted in North America 
between 1999–2004 were used for the model. This study concluded that donepezil
was associated with a lower rate of progression to Alzheimer’s Disease (AD) during 
the ﬁ rst 12 months of treatment in MCI patients, although the rate of progression to 
AD after three years was not lower among patients with donepezil than among those
given placebo. Our model examined several scenarios including different prevalence 
estimates for the APOE e 4 gene, a risk factor for developing AD and different treat-
ment strategies (with and without Donepezil). Extensive sensitivity analyses were 
performed on the probability of progressing to AD, health state utility and health care 
costs. RESULTS: Over 3 years preventive treatment of MCI patients is predicted to 
result in the gain of 0.015 QALYs, when comparing to usual care. The Incremental
cost was CAD $ 595 with donepezil treatment; consequently, the incremental cost-
effectiveness ratio (ICER) is estimated to be $81,599 when the APOE e 4 gene prob-
ability is 0.55. With a probability of 0.36, the average in developed countries, the
ICER is CAD $103,245. Results were less sensitive in the scenario with a lesser prob-
ability of APOE e 4. CONCLUSIONS: Genetic testing in combination with preventive 
donepezil treatment for MCI patients may not be economically attractive in this 
setting. Under certain assumptions, however, this intervention might be cost-effective 
for MCI patients due to delayed onset of AD.
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OBJECTIVES: Previous cost-effectiveness studies have modeled Alzheimer’s disease
(AD) progression in terms of cognitive function alone, a single global severity measure,
or progression to the need for “Full Time Care.” This study estimates AD progression 
in terms of correlated changes in cognition, behavior and function. These projections
are then used to analyze the cost-effectiveness of donepezil versus standard care in the
UK. METHODS: Patient-level data from eight randomized placebo-controlled done-
pezil trials and a seven-year follow-up registry provided the basis for modeling longi-
tudinal rates of change in cognition (MMSE), behavior (Neuropsychiatric Inventory), 
activities of daily living and Instrumental Activities of Daily Living. A discrete event 
simulation is used to project outcomes for two patient groups, identical except for
treatment: donepezil 10mg per day versus untreated. Patient mix and costs were 
developed from UK-speciﬁ c literature. Costs are reported in 2007 British pounds. The 
discount rate is 3.5%. RESULTS: After ten years, patients with mild to moderately 
severe AD (26 qMMSE q 10) on donepezil are better off than those without treatment,
with costs reduced from both health care system and societal perspectives, savings 
averaging a1421 and a4094 per patient respectively. Donepezil-treated patients experi-
ence 0.12 more QALYs per patient and their caregivers 0.01 QALYs compared to 
untreated patients and their carers. In sensitivity analyses, dominance holds over a 
wide range of inputs, including when treatment effects, the impact of disease severity 
on caregiver time and patient utility, and institutionalization rates are decreased by 
25%; or when the time horizon is decreased to 5 years. In probabilistic sensitivity 
analyses, donepezil dominates in 53 to 77% of replications (depending on perspective),
and results in cost/QALY estimates below a30,000 in 79 to 90% of replications. 
CONCLUSIONS: These results suggest that donepezil is highly cost-effective in 
patients with mild to moderately severe AD in the UK.
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OBJECTIVES: The cost-effectiveness of screening adults presenting with subjective
memory complaints and treating those diagnosed with Alzheimer’s disease (AD) with 
donepezil 10 mg is examined for the UK. METHODS: Patient-level data from eight
randomized placebo-controlled donepezil trials and a seven-year follow-up registry 
were used to model correlated longitudinal rates of change and treatment effects in 
cognition, behavior, and function. Using UK AD prevalence and diagnosis patterns, a 
discrete event simulation projects outcomes for annual screening of patients aged over
65 reporting memory complaints, compared to no screening or donepezil treatment.
Patients with undiagnosed AD are assumed to report memory complaints between 
onset of the disease and the time they would have been diagnosed in the absence of 
screening (on average, 36 months from disease onset). RESULTS: Seventeen patients
need to be screened to diagnose one patient with AD. Screening costs average a5,100 
per patient diagnosed. Over a ten year time horizon, screening and treating reduces
total direct costs by an average of over a2,500 per diagnosed patient, and indirect costs 
by almost a4,500 per patient. QALYs gained with screening and donepezil treatment
average 0.17 per patient, compared to 0.12 QALYs per patient with donepezil treat-
ment when diagnosis is delayed in the absence of screening. QALY gains for caregivers 
are 0.02. In probabilistic sensitivity analyses, screening dominates no treatment in 31%
to 63% of replications (depending on perspective), and results in cost/QALY estimates
below a30,000 in 79% to 86% of replications. Overall, probabilistic analyses yielded 
a mean incremental cost-effectiveness ratio of a7,467/QALY if only direct costs were 
considered, and dominance from a societal perspective. CONCLUSIONS: Although 
screening has signiﬁ cant upfront costs, identifying and treating AD patients early results
in overall cost savings and QALY beneﬁ ts compared to no treatment, and larger QALY 
beneﬁ ts than treatment following delayed diagnosis without screening.
